Moffitt Cancer Center: Clinical Trial 20286

RESEARCH

Call Today

1-888-663-3488

COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More

Facebook

Twitter

Linkedin

Pinterest

Email

Clinical Trials Search

Back to Search Results

Clinical Trial 20286

Cancer Type: Gastrointestinal Tumor
Study Type: Treatment
NCT#: NCT03972488

Phase: Phase III
Prinicipal Investigator: Jonathan Strosberg

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

A Phase III Multi-Center, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Lutathera in Patients with Grade 2 and Grade 3 Advanced GEP-NET

Summary

Objective

Primary Objective: To demonstrate that Lutathera is superior to active comparator in delaying the time-to-first occurrence of progression or death (PFS) as first line treatment Key Secondary Objectives: To demonstrate the superiority of Lutathera, compared to active comparator, in terms of objective response. To demonstrate the superiority of Lutathera, compared to active comparator, in terms of time to deterioration in selected QoL items/scales

Treatments

Therapies

Medications

177Lu-DOTA0-Ty3-Octreotate (Lutathera); Lutathera (); octreotide LAR ()

Inclusion Criteria

Presence of metastasized or locally advanced, inoperable (curative intent) histologically proven, well differentiated Grade 2 or Grade 3 gastroenteropancreatic neuroendocrine (GEP-NET) tumor diagnosed within 6 months prior to screening.

Ki67 index ≥10 and ≤ 55%

Patients ≥ 15 years of age and a body weight of > 40 kg at screening

Expression of somatostatin receptors on all target lesions documented by CT/MRI scans, assessed by the following somatostatin receptor imaging (SRI) modalities within 3 months prior to randomization: [68Ga]-DOTA-TOC (e.g. Somakit-TOC) PET/CT imaging or [68Ga]-DOTA-TATE PET/CT imaging (e.g. NETSPOT) or Somatostatin Receptor scintigraphy (SRS) with 111In-pentetreotide (Octreoscan SPECT/CT).

The tumor uptake observed in the target lesions must be > normal liver uptake observed on planar imaging.

Karnofsky Performance Score (KPS) ≥ 60

Presence of at least 1 measurable site of disease

Patients who have provided a signed informed consent form to participate in the study, obtained prior to the start of any protocol related activities

Exclusion Criteria

Exclusion Criteria:

Lab values as indicated per protocol

Pregnancy or lactation

Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, are not allowed to participate in this study UNLESS they are using highly effective methods of contraception throughout the study and for 6 months after study drug discontinuation

Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization in the study.

Documented RECIST progression to previous treatments for the current GEP-NET at any time prior to randomization

Patients for whom in the opinion of the investigator other therapeutic options (eg chemo-, targeted therapy) are considered more appropriate than therapy offered in the study, based on patient and disease characteristics

Any previous therapy with Interferons, Everolimus (mTOR-inhibitors), chemotherapy or other systemic therapies administered for more than 1 month and within 12 weeks prior to randomization in the study.

Any previous radioembolization, chemoembolization and radiofrequency ablation

Any surgery within 12 weeks prior to randomization in the study

Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks, prior to screening in the study. Patients with a history of brain metastases must have a head CT with contrast to document stable disease prior to randomization in the study.

Uncontrolled congestive heart failure (NYHA II, III, IV). Patients with history of congestive heart failure who do not violate this exclusion criterion will undergo an evaluation of their cardiac ejection fraction prior to randomization, preferably via gated equilibrium radionuclide ventriculography. The results from an earlier assessment (not exceeding 30 days prior to randomization) may substitute the evaluation at the discretion of the Investigator, if no clinical worsening is noted. The patient's measured cardiac ejection fraction in these patients must be ≥40% before randomization.

QTcF > 470 msec for females and QTcF > 450 msec for males or congenital long QT syndrome

Uncontrolled diabetes mellitus as defined by a fasting blood glucose > 2 ULN

Hyperkaleamia > 6.0 mmol/L (CTCAE Grade 3) which is not corrected prior to study enrolment

Any patient receiving treatment with short-acting octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of Lutathera, or any patient receiving treatment with SSAs (e.g. octreotide long-acting), which cannot be interrupted for at least 6 weeks before the administration of Lutathera, unless the tumor uptake on target lesions observed by study-permitted somatostatin receptor imaging (SRI) modalities during continued long-acting SSA treatment is greater than the liver uptake observed by planar imaging.

Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with the completion of the study.

Prior external beam radiation therapy to more than 25% of the bone marrow.

Current spontaneous urinary incontinence

Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years

Patient with known incompatibility to CT Scans with IV contrast due to allergic reaction or renal insufficiency. If such a patient can be imaged with MRI, then the patient would not be excluded.

Patients with known intolerance or hypersensitivity to any somatostatin analogs

Patients who have participated in any therapeutic clinical study/received any investigational agent within the last 30 days

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.